Accordingly, there has been evidence that the activation of the ACE2/Ang1-7/Mas receptor axis protects against NAFLD through multiple mechanisms including inhibition of hepatic lipogenesis, enhancement of FFA oxidation, and inhibition of inflammation [20–22]. Here, ACE2 is linked to metabolic dysfunction-associated steatotic liver disease.